髄膜炎菌ワクチン：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 Pathophysiology 25
3.2 Symptoms 27
3.3 Prognosis 28
4 Epidemiology 29
4.1 Disease Background 29
4.2 Risk Factors and Comorbidities 30
4.2.1 Infants and Young Children are at Greatest Risk for Developing Meningococcal Disease 30
4.2.2 Direct Contact and Overcrowding are the Primary Risk Factors for Infection 31
4.2.3 Exposure is Highest for Those Traveling to the African “Meningitis Belt” 32
4.3 Global Trends 33
4.3.1 US 33
4.3.2 5EU 34
4.3.3 Australia 35
4.3.4 Brazil 36
4.4 Forecast Methodology 37
4.4.1 Sources Used 39
4.4.2 Forecast Assumptions and Methods 44
4.4.3 Sources Not Used 49
4.5 Epidemiology Forecast of Meningococcal Disease (2012-2022) 50
4.5.1 Incident Cases of Meningococcal Disease 50
4.5.2 Age-Specific Incident Cases of Meningococcal Disease 53
4.5.3 Incident Cases of Meningococcal Disease By Serogroup 56
4.6 Discussion 58
4.6.1 Conclusions on Epidemiological Trends 58
4.6.2 Limitations of the Analysis 59
4.6.3 Strengths of the Analysis 60
5 Disease Management 61
5.1 Meningococcal Immunization Policy 62
5.2 US 65
5.2.1 Meningococcal Immunization Recommendations and Policies 65
5.2.2 Clinical Practice 68
5.3 France 70
5.3.1 Meningococcal Immunization Recommendations and Policies 70
5.3.2 Clinical Practice 72
5.4 Germany 74
5.4.1 Meningococcal Immunization Recommendations and Policies 74
5.4.2 Clinical Practice 75
5.5 Italy 76
5.5.1 Meningococcal Immunization Recommendations and Policies 76
5.5.2 Clinical Practice 77
5.6 Spain 78
5.6.1 Meningococcal Immunization Recommendations and Policies 78
5.6.2 Clinical Practice 79
5.7 UK 81
5.7.1 Meningococcal Immunization Recommendations and Policies 81
5.7.2 Clinical Practice 83
5.8 Japan 85
5.8.1 Meningococcal Immunization Recommendations and Policies 85
5.8.2 Clinical Practice 85
5.9 Australia 86
5.9.1 Meningococcal Immunization Recommendations and Policies 86
5.9.2 Clinical Practice 88
5.10 Brazil 90
5.10.1 Meningococcal Immunization Recommendations and Policies 90
5.10.2 Clinical Practice 91
6 Competitive Assessment 93
6.1 Overview 93
6.2 Strategic Competitor Assessment 93
6.3 Product Profiles – Major Brands 95
6.3.1 Menactra 95
6.3.2 Menveo 102
6.3.3 Nimenrix 107
6.3.4 MenHibrix 111
6.3.5 Menitorix 116
6.3.6 Meningitec 120
6.3.7 Menjugate 124
6.3.8 NeisVac-C 128
6.3.9 Menomune 132
6.3.10 Bexsero 136
7 Opportunity and Unmet Need 141
7.1 Overview 141
7.2 Unmet Needs 142
7.2.1 Unmet Need: Protection Against Serogroup B Disease 142
7.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 143
7.2.3 Unmet Need: More Cost-Effective Vaccines 144
7.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 145
7.2.5 Unmet Need: Immunogenic Infant Vaccines 147
7.2.6 Unmet Need: Improved Vaccination Coverage Rates 148
7.2.7 Unmet Need: Increased Patient Awareness and Education 149
7.3 Unmet Needs Gap Analysis 150
7.4 Opportunities 151
7.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 151
7.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 152
7.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 153
8 Pipeline Assessment 154
8.1 Overview 154
8.2 Clinical Trial Mapping 155
8.2.1 Clinical Trials by Country 155
8.3 Clinical Trials by Phase and Trial Status 157
8.4 Promising Vaccines in Clinical Development 159
8.4.1 MnB rLP2086 162
8.5 Promising Vaccines in Early Clinical Development 169
8.5.1 Meninge ACYW conj. 170
8.5.2 MenABCWY 174
8.5.3 MenC conjugate 177
8.5.4 Heptavalent DTP-Hib-HepB-IPV-MenC 180
9 Current and Future Players 183
9.1 Overview 183
9.2 Trends in Corporate Strategy 187
9.3 Company Profiles 189
9.3.1 Sanofi 189
9.3.2 Novartis 193
9.3.3 GlaxoSmithKline 197
9.3.4 Baxter 200
9.3.5 Nuron Biotech 202
9.3.6 Pfizer 204
10 Market Outlook 206
10.1 Global Markets 206
10.1.1 Forecast 206
10.1.2 Drivers and Barriers – Global Issues 210
10.2 United States 214
10.2.1 Forecast 214
10.2.2 Key Events 218
10.2.3 Drivers and Barriers 219
10.3 France 223
10.3.1 Forecast 223
10.3.2 Key Events 227
10.3.3 Drivers and Barriers 228
10.4 Germany 230
10.4.1 Forecast 230
10.4.2 Key Events 233
10.4.3 Drivers and Barriers 234
10.5 Italy 236
10.5.1 Forecast 236
10.5.2 Key Events 239
10.5.3 Drivers and Barriers 240
10.6 Spain 242
10.6.1 Forecast 242
10.6.2 Key Events 245
10.6.3 Drivers and Barriers 246
10.7 United Kingdom 248
10.7.1 Forecast 248
10.7.2 Key Events 252
10.7.3 Drivers and Barriers 253
10.8 Japan 255
10.8.1 Drivers and Barriers 255
10.9 Australia 257
10.9.1 Forecast 257
10.9.2 Key Events 261
10.9.3 Drivers and Barriers 262
10.10 Brazil 264
10.10.1 Forecast 264
10.10.2 Key Events 267
10.10.3 Drivers and Barriers 268
11 Appendix 270
11.1 Bibliography 270
11.2 Abbreviations 292
11.3 Methodology 295
11.4 Forecasting Methodology 295
11.4.1 Vaccine Coverage 296
11.4.2 Vaccine Approval vs. Routine Schedule Inclusion 296
11.4.3 Vaccines Included 297
11.4.4 Key Launch Dates 298
11.4.5 General Pricing Assumptions 299
11.4.6 Individual Vaccine Assumptions 300
11.4.7 Pricing of Pipeline agents 307
11.5 Physicians and Specialists Included in this Study 308
11.6 About the Authors 312
11.6.1 Authors 312
11.6.2 Reviewers 312
11.6.3 Epidemiologists 313
11.6.4 Global Head of Healthcare 314
11.7 About GlobalData 315
11.8 Disclaimer 315